Merck & Co., Inc. (MRK) News Today

Merck & Co., Inc. (NYSE: MRK) is trading higher as a broader biotechnology and vaccine-sector rally combines with favorable company-specific developments. However, analysts remain divided, and patent-related risks continue to weigh on the outlook.

• Positive Sentiment: Merck is participating in a broad rally across biotechnology and vaccine stocks, providing sector-wide momentum for MRK shares. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive Sentiment: The FDA approved Merck’s WELIREG plus LENVIMA combination for adults with advanced kidney cancer previously treated with PD-1 or PD-L1 therapies. The approval expands Merck’s oncology opportunity beyond its core Keytruda franchise. Merck also started a Phase I trial involving Cyprumed’s oral peptide-delivery platform, adding a potential pipeline catalyst. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while Morgan Stanley maintained or issued a Buy view in separate coverage. These actions suggest some analysts see the recent weakness and long-term growth prospects as attractive. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, although the position is too small to materially affect Merck’s fundamentals. Apella Capital Increases Stake in Merck
• Negative Sentiment: A Dutch court blocked Merck’s planned subcutaneous Keytruda product in eight European markets amid a patent dispute with Halozyme. The ruling could delay a potentially important reformulation and complicate efforts to extend Keytruda’s commercial life. HALO Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Merck is viewed as one of the pharmaceutical companies most exposed to upcoming patent losses and generic competition, raising longer-term concerns about revenue after Keytruda’s exclusivity period. Analysts have also flagged mixed growth prospects, while Morgan Stanley issued a separate pessimistic forecast. Pharma’s $500 Billion Patent Problem Will Come in Waves